China can achieve transition from a major pharmaceutical nation to a global powerhouse through regulatory science and full-chain innovation, Xu Huaqiang, founder and CEO of Cascade Pharmaceuticals, told Yicai at BioShanghai Week 2026. By seamlessly connecting R&D, clinical trials, and market access, the industry aims to deliver truly valuable innovative therapies to patients, he added.